Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI EAFE ETF (IEFA) vs Invesco Ltd. (IVZ) Price & Performance

iShares Core MSCI EAFE ETFTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

iShares Core MSCI EAFE ETF vs Invesco Ltd. — how do they compare? iShares Core MSCI EAFE ETF trades at $96.47 (market cap $189.19B), while Invesco Ltd. trades at $29.54 (market cap $13.28B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 14.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Invesco Ltd. for 77 Days on average.

IEFAIVZ
Market Cap
$189.19B$13.28B
Volume
8,441,7873,698,033
Sector
Broad Market / FactorFinancials
52-Week High
$101.41$33.31
52-Week Low
$85.06$22.44
Typical Hold Time
40 Days77 Days
Enterprise Value
—$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI EAFE ETF

IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.

The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.

Invesco Ltd.

Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.

The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IEFA
100% Buy0% Sell
Avg holding period · 40 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →